Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (46 page)

BOOK: Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine
13.91Mb size Format: txt, pdf, ePub
• Prevention: vaccinate all infants & children and at-risk adults (3 doses 0, 1 & 6–12 mo) • Postexposure (risk infxn ~30%) ppx: HBIG → vaccine (if unvac or known nonresponder)

Hepatitis C
(ssRNA; ~10% of acute viral hepatitis in U.S.;
NEJM
2011;364:2429)
• Transmission: blood (IVDU, transfusion) >> sexual; 20–30% w/o clear precipitant • Incubation: 1–5 mo; mean 6–7 wk

• Natural hx
acute infxn: 80% subclinical; 10–20% sx hepatitis w/ jaundice; fulminant hepatitis very rare; prob of spont clearance a/w
IL28B
& HLA class II genotypes (
Annals
2013;158:235)
chronic: up to 85% → chronic hepatitis, 20–30% of whom develop cirrhosis (after ~20 y) ↑ risk of cirrhosis in men, EtOH, HIV; HCC in 2–5% of cirrhotics/y
• Extrahepatic syndromes: cryoglobulinemia, porphyria cutanea tarda (blistering rash in sun-exposed areas), MPGN, MGUS, IPF, NHL and DM
• Serologic, virologic, & genetic tests
anti-HCV (ELISA):
in 6 wk, does
not
= recovery or immunity; can be
after recovery
HCV RNA:
w/in 2 wk, marker of active infection
HCV RIBA: used to confirm
anti-HCV ELISA in Pts w/ undetectable HCV RNA
HCV genotype (1–6): guides duration & predicts response to Rx
• Dx:
acute
hepatitis =
HCV RNA, ± anti-HCV;
resolved
=
HCV RNA, ± anti-HCV;
chronic
=
HCV RNA,
anti-HCV
• Treatment indications (
Hep
2009;49:1335 & 2011;54:1433;
NEJM
2013;368:1907)
Acute: if no spont. clearance at 8–12 wk, consider PEG-IFNɑ-2a/b ± RBV × 12–24 wk
Chronic: RNA
, plus bx w/ either chronic hepatitis & fibrosis stage >1 or compensated liver disease (in genotype 2 or 3, may proceed to Rx w/o bx b/c high response rate)

Triple therapy
(genotype 1):
PEG-IFN ɑ-2a/b, RBV, & protease inhibitor
(PI), either boceprevir (BOC) or telaprevir (TVR) (
NEJM
2011;364:1195 & 2405). Rx 24–48 wk; SVR rate 30–80% based on variables such as advanced fibrosis,
IL28B
genotype, prior response to IFN and rapid virologic resp ( RNA at wk 4 [TVR] or wk 8 [BOC]) (
Gastro
2012;142:1314) •
Dual therapy
(genotypes 2 & 3): PEG-IFNɑ-2a/b + RBV; Rx 24 wk; SVR rate ~80%
• Goal is
sustained virologic response
(SVR) =  viremia 24 wk after completion of Rx • IFN-free regimens incl. replic. complex, polymerase, & microRNA-122 inhibs. & other direct acting antivirals under study (
NEJM
2012;366:216; 2013;368:34, 45, 1685, 1867 & 1878) • Risks of Rx: flu-like sx, psych sx (if depressed can give SSRI), thyroid dysfxn, marrow suppression (can give EPO & G-CSF), hemolysis (RBV), sexual dysfxn; PIs w/ sig drug-drug interactions, worsen anemia, & TVR a/w rash/pruritus in 6%, DRESS/SJS in <1%
• Contraindic.: decompensated cirrhosis, preg, severe psych illness, active substance abuse, severe cardiac/pulm disease, uncontrolled DM, seizure d/o, autoimmune disease • CDC rec screening for HCV in anyone born 1945–1965 (
Annals
2012;156:263) • Vaccinate all chronic HCV patients against HBV and HAV if not immune
• Postexposure (needlestick risk ~3%) ppx: none; if HCV RNA →
, consider Rx w/in 3 mo
Hepatitis D
(RNA)
• Transmission: blood or sexual; endemic in Africa & E. Europe
• Pathogenesis: requires HBV to cause either simultaneous or superimposed infection
• Natural hx: in HBV ↑ severity of infxn and ↑ progression to cirrhosis and HCC in chronic carriers; clears w/ HBV
• Serologic/virologic tests: anti-HDV; follow HDV RNA during Rx (high relapse rate)

Hepatitis E
(ssRNA;
NEJM
2012;367:1237;
Lancet
2012;379:2477)
• In endemic areas most common cause of acute viral hepatitis

Other books

Love's Healing Touch by Jane Myers Perrine
The Shadowcutter by Harriet Smart
Scandal Wears Satin by Loretta Chase
Decadent by Elaine White
Near Enemy by Adam Sternbergh
Unforgettable - eARC by Eric James Stone